PetMed Express Inc. (PETS) - 10-K Summary
Business Context and Reporting Period
Company: PetMed Express, Inc. (d/b/a PetMeds and PetCareRx)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended March 31, 2026
Business Overview: A leading direct-to-consumer online pet pharmacy and retailer of prescription medications, OTC health products, and pet supplies for dogs, cats, and horses. The company operates via websites, mobile apps, and a customer contact center. It acquired PetCareRx in April 2023 to expand its product catalog beyond core prescriptions.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Net Sales | $179.0 million | $227.0 million | (21.1%) |
| Gross Profit | $50.2 million | $69.1 million | (27.4%) |
| Gross Margin | 28.0% | 30.5% | (250 bps) |
| Net Loss | $(57.3) million | $(6.3) million | Worsened by $51.0M |
| Operating Cash Flow | $(28.4) million | $4.7 million | Turned Negative |
| Cash & Equivalents (End of Period) | $21.4 million | $54.7 million | $(33.3) million |
| Working Capital | $(8.4) million | $16.1 million | $(24.5) million |
| Debt | $0 | $0 | N/A |
Note: The Net Loss includes a non-cash goodwill impairment charge of $26.7 million and an intangible asset impairment of $0.6 million.
Material Changes vs. Prior Period
- Revenue Decline: Sales dropped 21.1% primarily due to a 21.4% decrease in reorder sales (driven by prescription medication declines) and a 20.5% drop in new order sales (due to strategic reductions in paid media advertising).
- Margin Compression: Gross margin decreased to 28.0% from 30.5%, impacted by a $2.1 million inventory write-down related to non-prescription products from a failed wholesale transaction.
- Expense Increases: General and Administrative (G&A) expenses rose 31.3% to $50.7 million. This was driven by a $8.0 million increase in stock-based compensation (due to the non-recurrence of a one-time reversal in 2025) and $5.0 million in professional fees (including $3.2 million for a whistleblower investigation).
- Impairments: The company recorded a full goodwill impairment of $26.7 million and a $0.6 million impairment of the PetCareRx trade name due to downward revenue forecasts and sustained stock price declines.
- Liquidity Deterioration: Operating cash flow turned negative ($28.4M outflow) compared to a positive $4.7M inflow in the prior year. Working capital shifted from positive to negative.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management identified conditions (declining cash, recurring losses, negative operating cash flow) that raised substantial doubt about the company's ability to continue as a going concern. However, management concluded this doubt is alleviated by a plan involving advertising optimization, expense reductions, and capital expenditure cuts.
- Internal Control Weaknesses: The company disclosed material weaknesses in internal controls over financial reporting related to Sales Taxes, IT General Controls (ITGCs), Revenue Recognition, and Cooperative Advertising. While weaknesses in Income Taxes, Complex Accounting, and Tone at the Top were remediated, the others remain unremediated as of March 31, 2026.
- Strategic Outlook: Focus is on transitioning to a "best-in-class pharmacy provider," modernizing technology (ERP migration), and expanding AutoShip/membership programs (which generated 62.6% of Q4 sales).
- Dividends: The quarterly dividend was suspended indefinitely in February 2024 to preserve cash for growth and operations.
- Acquisition Proposals: In December 2025, the company received unsolicited non-binding proposals to acquire the company at $4.00-$4.25 per share. The Board declined to proceed with these specific proposals but remains open to future offers.
- Legal Risks: Ongoing class-action litigation regarding "false reference pricing" (alleged illusory discounts) in Pennsylvania and New York.
Key Facts for Investor Verification
- Cash Burn Rate: Verify the sustainability of the $21.4 million cash balance given the $28.4 million negative operating cash flow and the plan to reduce expenses.
- Remediation of Controls: Monitor progress on remediating the remaining material weaknesses in Sales Taxes, ITGCs, and Revenue Recognition, which pose risks to financial reporting accuracy.
- Prescription Sales Trend: Assess whether the decline in prescription reorder sales is a temporary market fluctuation or a structural shift in customer behavior or competitive landscape.
- Inventory Management: Review future inventory write-down risks, particularly regarding non-prescription SKUs, following the $2.1 million charge in FY2026.
- Legal Exposure: Track the status of the class-action lawsuits regarding pricing practices and potential settlement costs.